Association between statin therapy and reductions in atrial fibrillation or flutter and inappropriate shock therapy

Europace

Volumn 10, Issue 7, 2008, Pages 854-859

  Bhavnani, Sanjeev P ^a   Coleman, Craig I ^a,b   White, Charles M ^a,b   Clyne, Christopher A ^a   Yarlagadda, Ravi ^a   Guertin, Danette ^a   Kluger, Jeffrey ^a,b  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Atrial tachyarrhythmias; Implantable cardioverter defibrillator; Inappropriate shock therapy; Statins

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ATORVASTATIN; DIGOXIN; DOFETILIDE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; ROSUVASTATIN; SIMVASTATIN; SOTALOL;

ADULT; AGED; CONFERENCE PAPER; DEFIBRILLATION; DEFIBRILLATOR; DRUG USE; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; ATRIAL FIBRILLATION; ATRIAL FLUTTER; COHORT STUDIES; DEFIBRILLATORS, IMPLANTABLE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 45849103792     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eun128     Document Type: Conference Paper

References (34)

1. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;3:225-37.
2. The Antiarrhythmic versus Implantable Cardioverter Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable cardioverter defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-83.
3. Schron EB, Exner DV, Yao Q, Jenkins LS, Steinberg JS et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 2002;105:589-94.
4. Irvine J, Dorian P, Baker B, O'Brien BJ, Roberts R, Gent M et al. Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am Heart J 2002;144:282-9.
5. Rienstra M, Smit MD, Nieuwland W, Tan ES, Wiesfeld AC, Anthonio RL et al. Persistent atrial fibrillation is associated with appropriate shocks and heart failure in patients with left ventricular dysfunction treated with an implantable cardioverter defibrillator. Am Heart J 2007;143:120-6.
6. Hanna IR, Heeke B, Bush H, Brosius L, King-Hageman D, Dudley SC Jr et al. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 2006;3:881-6.
7. Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Covino E et al. Randomized trial of atrovastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery; results of the ARMYDA-3 (atrovastatin for reduction of myocardial dysrhythmia after cardiac surgery) study. Circulation 2006;114:1455-66.
8. Go AS, Lee WY, Yang J, Lo JC, Gurwitz JH. Statin therapy and risks of death and hospitalization in chronic heart failure. JAMA 2006;296:2105-11.
9. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007;147:573-7.
10. Nanthakumar K, Dorian P, Paquette M, Greene M, Edwards J, Heng D et al. Is inappropriate implantable defibrillator shock therapy predictable? J Interv Card Electrophysiol 2003;3:215-20.
11. Dickinson MG, Ip JH, Olshansky B, Hellkamp AS, Anderson J, Poole JE et al. Statin therapy was associated with reduced atrial fibrillation and flutter in heart failure patients in SCD-HeFT. Heart Rhythm 2006;3:S49.
12. Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Covino E et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (atorvastatin for reduction of myocardial dysrhythmia after cardiac surgery) study. Circulation 2006;3:1455-61.
13. Dernellis J, Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J 2005;150:1064.
14. Ozaydin M, Varol E, Aslan SM, Kucuktepe Z, Dogan A, Ozturk M et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 2006;97:1490-3.
15. Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboys T, Bilchik B et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003;92:1379- 83.
16. Tsai CT, Wang YC, Lai LP. Atorvastatin prevents atrial fibrillation in patients with implantation of a pacemaker: a prospective randomized trial. (Abstract PO1-35). Heart Rhythm 2007;4:S141-68.
17. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP et al. Incidence of an risk factors for atrial fibrillation in older adults. Circulation 1997;96:2455-61.
18. Connolly SJ, Kerr CR, Gent M, Roberts RS, Yusuf S, Gillis AM et al. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian trial of physiologic pacing investigators. N Engl J Med 2000;342:1385-91.
19. Jahangir A, Shen WK, Neubauer SA, Ballard DJ, Hammill SC, Hodge DO et al. Relation between mode of pacing and long-term survival in the very elderly. J Am Coll Cardiol 1999;33:1208-16.
20. Sweeney MO, Wathen MS, Volosin K, Abdalla I, DeGroot PJ, Otterness MF et al. Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients. Circulation 2005;111:2898- 905.
21. Sparks PB, Mond HG, Vohra JK, Jayaprakash S, Kalman JM. Electric remodeling of the atria following loss of atrioventricular synchrony: a long term study in humans. Circulation 1999;100:1894-900.
22. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
23. Olshansky B, Day JD, Moore S, Gering L, Rosenbaum M, McGuire M et al. Is dual chamber programming inferior to single-chamber programming in an implantable cardioverter defibrillator? Results of the INTRINSIC RV (inhibition of unnecessary RV pacing with AVSH in ICDs) study. Circulation 2007;115:9-16.
24. Dijkman B, Wellens HF. Dual chamber arrhythmia detection in the implantable cardioverter defibrillator. J Cardiovasc Electrophysiol 2002;13:S31-9.
25. Swerdlow CD, Schsls W, Dijkman B, Jung W, Sheth NV, Olson WH et al. Detection of atrial fibrillation and flutter by a dual-chamber implantable cardioverter defibrillator. Circulation 2000;101:878- 85.
26. Ricci R, Pignalberi C, Disertori M, Capucci A, Padeletti L, Botto G et al. Efficacy of a dual chamber defibrillator with atrial antitachycardia functions in treating spontaneous atrial tachyarrhythmias in patients with life-threatening ventricular tachyarrhythmias. Eur Heart J 2002;23:1471-9.
27. Gradaus R, Seidl K, Korte T, Himmrich E, Wieneke H, Schuchert A et al. Reduction of ventricular tachyarrhythmia by treatment of atrial fibrillation in ICD patients with dual-chamber implantable cardioverter/ defibrillators capable of atrial therapy delivery: the REVERT-AF study. Europace 2007;9:534-9.
28. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2007;116:257-354.
29. Pollack WM, Simmons JD, Interian A, Castellanos A, Myerburg RJ, Mitrani RD. Pacemaker diagnostics: a critical appraisal of current technology. PACE 2003;26:76-98.
30. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-8.
31. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA et al. Effect of intensive compared with moderate lipid lowering therapy on progression of coronary atherosclerosis. JAMA 2004;291:1071-80.
32. Rosenson RS. Statins in atherosclerosis: lipid lowering agents with antioxidant capabilities. Atherosclerosis 2004;173:1-12.
33. Shishehbor MH, Aviles RJ, Brennan ML, Fu X, Goormastic M, Pearce GL et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 2003;289:1675-80.
34. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-61.